Why These 15 Healthcare Stocks Are Surging in 2025

13. Monopar Therapeutics Inc (NASDAQ:MNPR)

Number of Hedge Fund Holders In Q4 2024: 5

Monopar Therapeutics Inc (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company developing novel radiopharmaceuticals for oncology and a late-stage treatment for Wilson disease called ALXN1840.

The stock’s strong move in 2025 has been propelled by a series of material events, starting with the in-licensing of ALXN1840 from Alexion, AstraZeneca Rare Disease in October 2024.

This deal included a $4 million upfront payment, equity issuance, and future milestone and royalty payments, giving Monopar exclusive global rights to a Phase 3-ready asset that met its primary endpoint for Wilson disease.

In the fourth quarter of 2024 and into early 2025, Monopar strengthened its financial position by raising over $55 million through public offerings and private placements, with a notable $19.2 million offering priced at $16.25 per share in March 2025. The company also initiated two first-in-human Phase 1 clinical trials for its radiopharmaceutical pipeline targeting advanced cancers, and announced plans to submit a New Drug Application for ALXN1840 in early 2026.

These developments, particularly the ALXN1840 licensing and the capital raises, led to substantial upward moves in the stock price.

The consensus price target of $55.33 implies 29.56% upside.

MNPR stock is up 94.14% year-to-date.